key: cord-0688114-rkokbi5c
authors: Fishman, Jay A.
title: The epidemiology of community‐acquired respiratory viruses during the SARS‐CoV‐2 pandemic
date: 2020-12-02
journal: Am J Transplant
DOI: 10.1111/ajt.16382
sha: df2838593b197f3bb8399767b417b7e5678a3302
doc_id: 688114
cord_uid: rkokbi5c

In regions of high COVID‐19 endemicity, the incidence of other respiratory viral illnesses is depressed, which may reflect biologic displacement of other pathogens or the impact of preventive strategies to reduce transmission of SARS‐CoV‐2.

The initial spread of SARS-CoV-2 from China coincided with the usual period for many community-acquired respiratory viruses regimen. 6 In one study of kidney recipients, vaccination in the first year after transplant was associated with a reduced rate of transplant rejection (aHR = 0.77; 95% CI 0.69, 0.85; P < .001) and death (aHR = 0.82; 95% CI 0.76, 0.89; P < .001). 7 High-dose vaccination may be advantageous in organ transplant recipients. 8 However, no preferential recommendation is made by ACIP for one influenza vaccine product over another.

Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project

Rates of co-infection between SARS-CoV-2 and other respiratory pathogens

Epidemiology of severe acute respiratory syndrome coronavirus 2 emergence amidst community-acquired respiratory viruses

Decreased influenza activity during the COVID-19 pandemic -United States

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices -United States, 2020-21 Influenza Season

Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice

Outcomes associated with influenza vaccination in the first year after kidney transplantation

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients